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Abstract
Introduction: Ovarian cancer is one 
of the most lethal gynecologic cancers. 
Relapses after remission are common, 
hence novel strategies are urgently 
needed. Our group has previously 
developed a vaccination approach 
based on dendritic cells pulsed with 
HOCl-oxidized tumor lysates. Here 
we investigate the improvement of this 
vaccine strategy using squaric acid treatment of cancer cells during tumor lysate preparation and by 
differentiating dendritic cells in the presence of GM-CSF and IFNα.
Methods: Induction of cell death by squaric acid treatment was assessed with propidium iodide (PI) 
and Annexin V in ID8 tumor cells. High mobility group box 1 (HMGB1) immunogenic status was 
analyzed using a western blot-based method, as previously described. For immunological tests, ID8 cells 
expressing ovalbumin (ova-ID8) were treated with squaric acid before cell lysis. DCs prepared with the 
canonical GM-CSF and IL-4 differentiation cocktail or IFNα and GM-CSF were pulsed with tumor cell 
lysates and further matured in the presence of IFNγ and LPS (4-DCs and α-DCs respectively). DCs were 
then used in co-culture assays with ova-specific T cells and IFNγ and IL-4 secretion measured by ELISA. 
DC phenotypes were characterized by FACS. Finally, DCs were tested in an ovarian cancer mouse model 
measuring body weight and animal survival.
Results: Squaric acid treatment of mouse ovarian cancer cells induced tumor cell death as well as preserve 
HMGB1, a crucial Damage-associated molecular pattern (DAMP) signal, in its active reduced form. 
Squaric acid treatment of ID8-ova cells increased IFNγ and decreased IL-4 production from ova-specific 
T cells in co-culture experiments, promoting a more immunogenic cytokine secretion pattern. DCs 
differentiated in the presence of IFNα induced a considerable decrease in IL-4 production compared 
to canonical 4-DCs, without affecting IFNγ release. DC phenotyping demonstrated a more mature and 
immunogenic phenotype for IFNα-differentiated DCs. Vaccination in tumor-bearing mice showed that 
IFNα-differentiated DCs pulsed with squaric acid-treated lysates were the most potent at delaying tumor 
growth, improving animal survival.
Conclusion: We identified squaric acid as a novel immunogenic treatment of tumor cells for cancer 
vaccines particularly efficient in prolonging animal survival when used in combination with IFNα-
differentiated DCs. These promising results support future efforts for the clinical translation of this 
approach.
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Introduction
Ovarian cancer is one of the most lethal gynecologic 
cancers with a dismal prognosis.1 Over 230 000 women are 
diagnosed with ovarian cancer worldwide each year, and 
about 140 000 women die from the disease.2 Unfortunately, 
most ovarian cancer cases are diagnosed at a late stage and 
have a 5-year survival rate of only 39%.2 Accumulating 
evidence shows that tumors can be spontaneously 
recognized and attacked by the immune system a fact that 
is associated with improved clinical outcomes.3,4 Hence, 
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it is postulated that immunotherapeutic vaccines could 
potentiate the anti-tumor immune response in ovarian 
cancer, especially when administered in the minimal 
residual disease setting. 
Dendritic cells (DCs) are the most potent antigen-
presenting cells in the immune system. Due to their unique 
ability to prime and stimulate both CD8+ and CD4+ T cells, 
DCs loaded with tumor antigens have been investigated in 
several clinical trials for their ability to induce therapeutic 
anti-tumor T cell responses.5,6 Historically, DCs used for 
vaccination purposes have mostly been differentiated from 
monocytes in the presence of GM-CSF and IL-4. More 
recently, different cytokine cocktails have been developed 
that could generate alternative DCs with enhanced 
potency to induce tumor-specific immune responses.7–12 
In particular, tumor vaccines have been developed using 
either single antigens or whole tumor lysate. The use of 
the whole tumor approaches for vaccination purposes has 
several advantages over the use of defined tumor antigens. 
Tumor cells express a whole array of tumor-associated 
antigens (TAAs) that can be defined or undefined, shared 
or patient-specific (e.g. neoantigens arising from somatic 
mutations in individual tumors). Although it is currently 
unknown for most tumor types which TAAs mediate 
tumor regression, mounting evidence indicates that these 
neoantigens are important in the response to immune 
checkpoint blockade.13–16 Another important feature of 
whole tumor approaches is the fact that they contain both 
MHC Class I and II restricted epitopes, allowing antigen 
presentation by DCs to both CD4+ and CD8+ T cells to 
generate stronger primary immune responses and to 
prevent the emergence of tumor escape variants.3 The use 
of the whole tumor approaches also obviates the need for 
HLA selection of patients since it is not restricted to the 
specific epitope(s) contrary to vaccination with defined 
peptide antigen(s).17
Interestingly, different methods have been employed 
to increase the immunogenic potential of whole tumor 
lysate as a source of antigens.18 Our group previously 
developed a potent vaccination approach consisting of 
autologous DCs pulsed with hypochloric acid (HOCl)-
oxidized autologous tumor lysate against ovarian cancer in 
humans.19,20 However, HOCl is a rather unstable molecule 
characterized by a short half-life. 
In the current study, we sought to alternate mild 
acid treatments to prepare tumor lysates for vaccine 
applications. We present a new immunogenic treatment 
of cancer antigens consisting in the use of squaric acid 
(SqA), a more stable molecule compared to HOCl and 
which is already clinically approved for the treatment of 
skin papillomas (so-called verrucae or warts) caused by 
an active skin infection by the human papilloma virus, 
a DNA virus. Given that HPV induced papillomas can 
be cured by the local application of SqA,21 we theorized 
that the use of SqA for killing tumor cells could induce 
immunogenic cell death and thereby elicit a potent 
antitumor immune response. Furthermore, given that the 
successful therapeutic application of SqA occurs in the 
context of an active DNA viral infection, we theorized that 
the use of interferon-alpha (IFNα) to differentiate DCs 
could provide an important additional stimulus aiding 
the generation of an antitumor immune response. Results 
presented here both in vitro and in vivo in ovarian cancer 
mouse models suggest that both SqA treatment of cancer 
antigens and DC differentiation in the presence of IFNα 
are more immunogenic than a previously tested tumor 
lysate-pulsed DC vaccine and efficiently prolong animal 
survival supporting the future clinical translation of this 
approach.
Materials and Methods
Tumor cell lines and mice
The ID8 cell line was a generous gift from Dr. Paul F. 
Terranova, University of Kansas. The ID8-ova cell line was 
generated by stable transfection of ID8 cells using Express-
in technology (Thermo Scientific, USA) with a construct 
of chicken ovalbumin (a kind gift from Dr. Y. Patterson, 
University of Pennsylvania) cloned in the pcDNA3.1-
zeocin mammalian expression vector (Life Technologies, 
Carlsbad, USA). Tumor cells were cultured in complete 
DMEM (Cellgro, New York, USA) containing 10% heat-
inactivated fetal bovine serum (FBS, Life Technologies) 
and antibiotics (Penstrep (Gibco, Gaithersburg, USA) at 
10 U/mL culture medium and normocin, (Invitrogen,  
Waltham, USA) at 0.1 mg/mL culture medium). 
Cells were regularly tested for mycoplasma. Specific 
pathogen-free grade 6-8 week-old female C57BL/6, OT-I 
(C57BL/6-Tg(TcraTcrb)1100Mjb/J) and OT-II (B6.Cg-
Tg(TcraTcrb)425Cbn/J) mice were purchased from the 
Jackson Laboratories, Sacramento, USA. Animals were 
maintained according to the institutional guidelines. 
Preparation of tumor lysate
To prepare freeze-thaw tumor lysates, ID8-ova cells 
were harvested, washed and resuspended at 108 cells/
ml in Mg+2/Ca+2-free DPBS containing the protease 
inhibitors complete mini tablet (Roche, Switzerland) and 
phosphatase inhibitors (PhosStop, Roche). Cells were then 
subjected to 6 cycles of freeze and thaw (snap freezing in 
liquid nitrogen and quick thawing at 37°C), followed by 
sonication (3 cycles of 5 W output for 15 seconds).
The HOCl-oxidized tumor lysate (ID8-ova-HOCl) 
was prepared as previously reported.20 Briefly, ID8-ova 
cells were resuspended in 60 µM HOCl (Sigma-Aldrich, 
Germany) solution at a cell density of 108 cells/mL and 
incubated for 1 hour at 37°C and 5% CO2, with gentle 
agitation every 30 minutes. Subsequently, HOCl-treated 
cells were centrifuged at 600 x g for 6 minutes, the 
supernatant was discarded and the cell pellet washed 
twice with DPBS, resuspended in 1 mL DPBS and then 
subjected to 6 freeze-thaw cycles followed by sonication, 
as described above. For the preparation of SqA-treated 
tumor lysate (ID8-ova-Sq), ID8-ova cells were incubated 
with the indicated concentrations of SqA (Sigma-Aldrich, 
Dendritic cells-based cancer vaccine
BioImpacts, 2018, 8(3), 211-221 213
Germany) for 1 hour at 37°C and 5% CO2 after which 
cells were washed and subjected to the 6 freeze-thaw cycle 
followed by sonication process described above.
 
Detection of cell death
To detect cell death, cells were first washed with DPBS 
and subsequently with 1X binding buffer (Biolegend, 
USA). Cells were then resuspended in 1X binding buffer 
at a 2x106 cell/mL concentration. 5 µL of annexin V-FITC 
(Biolegend, USA) were added to 100 µL of cell suspension, 
and incubated for 15 minutes at room temperature (RT) 
in the dark. Cells were then washed with 1X binding 
buffer and resuspended in 250 µL of 1X binding buffer. 
Five µL of a propidium iodide (Sigma-Aldrich, Germany) 
solution (0.1 mg/mL) was added. After 5 minutes, 1 mL 
of pre-warmed DPBS containing 2% BSA was added and 
the cells were subsequently analyzed by FACS BD Canto-
II (BD Biosciences, USA).
Determination of HMGB1 oxidation
The oxidation status of the high mobility group box 1 
(HMGB1) protein in response to HOCl or SqA treatment of 
ID8 cells was determined using the methoxypolyethylene 
glycol-maleimide (MAL-PEG) conjugation method as 
described by Makmura et al22 with minor modifications. 
Briefly, the ID8-Sq lysate was treated with 40 mM 
N-ethylmaleimide (Sigma-Aldrich, Germany) at RT 
with vigorous shaking to quench free sulfhydryl groups. 
After 2 hours incubation, the mixture was dialyzed 
against DPBS overnight at 4°C using a 10 kDa cut-off. 
DTT (Sigma-Aldrich, Germany) was then added at a 20 
mM final concentration and samples incubated at RT for 
30 minutes. Finally, MAL-PEG 20 000 (Sigma-Aldrich, 
Germany) was added at final 4 mM concentration and 
incubated for 1 hour at RT under constant shaking. 
β-mercaptoethanol-containing Laemmli buffer NuPAGE 
(Thermo Fisher, USA) was added to the samples which 
were then run on a 4%-12% gradient SDS-PAGE NuPAGE 
(Thermo Fisher, USA). Proteins were then transferred 
onto a PVDF membrane for 4 hours; the membrane was 
blocked with 2% BSA (Sigma-Aldrich, Germany) for 1 
hour and sampled first with the anti-HMGB1 antibody 
(Abcam, UK) followed by goat anti-rabbit-HRP (Abcam, 
UK). Bands were revealed by the chemiluminescence 
Pierce ECL kit (Thermo Fisher, USA).
Detection of ova protein by western blot and ELISA
One hundred microliters of the indicated cell lysate were 
mixed with 900 µL of the carbonate-bicarbonate buffer, pH 
9.5 and used to coat (100 µL/well) a Nunc maxisorp ELISA 
plate (Sigma-Aldrich, Germany). An ELISA assay was 
then performed using anti-ovalbumin-HRP polyclonal 
antibody (Abcam, UK) and TMB (BD Biosciences, USA) 
according to manufacturer instructions. For western blot, 
the indicated cell lysate samples were loaded on a 4%-
10% gradient SDS-PAGE NuPAGE gel (Invitrogen, USA). 
Proteins were then transferred onto a PVDF membrane 
for 4 hours; the membrane was blocked with 5% fat-free 
milk (Sigma-Aldrich, Germany) for 1 hour and sampled 
with anti-ova-HRP antibody (Abcam, UK). Bands were 
revealed by the chemiluminescence Pierce ECL kit 
(Thermo Fisher, USA).
Mouse bone marrow-derived DC preparation
DCs were generated from murine bone marrow cells, as 
described by Garrigan et al23 with minor modifications. 
Briefly, bone marrow was flushed from the long bones 
of C57BL/6 mice. A single cell suspension was cultured 
in RPMI 1640 (CellGro, USA) supplemented with 10% 
heat-inactivated FBS (Life Technologies, USA), 2 mM 
L-glutamine (Gibco, USA), 100 U/mL penicillin (Gibco, 
USA), 100 µg/mL streptomycin (Gibco, USA), 10 mM 
HEPES pH 7.4 (Gibco, USA), 0.5 mM sodium pyruvate 
(Cellgro, USA), 0.5% MEM non-essential amino acids 
(Cellgro, USA), 0.1 mg/mL Normocin (InVivogen, USA), 
along with 20 ng/mL GM-CSF (Peprotech) and 10 ng/
mL IL-4 (Peprotech, USA) for 4-DCs or 20 ng/mL GM-
CSF and 250 U/mL IFNα (AbD Serotec, USA) for α-DCs. 
On day 2, the medium was replaced with fresh medium 
containing the respective cytokines. On day 4, 100 µL 
of the indicated tumor lysate preparations were added 
to 10 mL culture (~1 tumor cell equivalent per DC) and 
incubated overnight at 37°C and 5% CO2. Unpulsed 
DCs were also cultured as negative controls. On day 5, 
the medium was removed and fresh medium containing 
100 ng/mL LPS (Sigma-Aldrich, Germany) and 100 ng/
mL IFNγ (Peprotech, USA) was added. DCs were then 
cultured overnight at 37°C and 5% CO2.
In vitro stimulation of T cells and cytokine analysis
T cells from spleens of OT-I and OT-II animals were 
purified by negative selection with Dynabeads (Invitrogen, 
USA) according to manufacturer protocol. 1x105 T cells 
were then plated in 96-well flat-bottom plates with 1x104 
DCs and cultured for 24 hours in a culture volume of 200 
µL. Cell-free culture supernatants were then harvested to 
measure IFNγ and IL-4 cytokine levels by ELISA using 
OptEIA ELISA sets (BD Biosciences, USA).
Dendritic cell phenotyping
Mature lysate-pulsed DCs were harvested and blocked 
with DPBS containing 2% FBS and anti-mouse CD16/
CD32 monoclonal antibody Fc Block (BD Biosciences, 
USA). Cells were subsequently stained for 15 minutes 
at 4°C with the following antibodies (Biolegend, USA): 
CD14-APC, F4/80-BV421, MHC-I (H-2Kb/H-2Db-PE), 
MHC-II (I-A/I-E-AF488), CD86-PE/Cy7, CD83-FITC or 
with the appropriate isotype-matched controls (Biolegend, 
USA). After staining, the cells were washed and fixed with 
2% w/v paraformaldehyde. For intracellular cytokine 
staining, cells were treated with brefeldin A (Sigma-
Aldrich, Germany) at 10 µg/mL for 4 hours at 37°C. 
Cells were then blocked, stained for appropriate surface 
markers as described above, washed twice and then fixed 
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and permeabilized using BD fixation/permeabilization 
kit (BD Biosciences, USA). Cells were subsequently 
incubated for 2 hours in blocking solution (1X BD Perm-
wash containing 1 µg/mL Fc Block), centrifuged and then 
stained for cytokines with the following antibodies: IFNγ-
AF488 (eBioscience, USA), IL-12p70-biotin (Invitrogen, 
USA) and streptavidin-APC (Invitrogen, USA), TNFα-
PE/Cy7 (eBioscience, USA), TFGβ1-LAP-PerCP/Cy5.5 
(Biolegend, USA), IL-10-PE (eBioscience, USA); or with 
appropriate isotypes controls in BD perm-wash. Cells were 
then washed twice and resuspended in DPBS containing 
2% FBS. Cells were analyzed by FACS BD-Canto II (BD 
Biosciences, USA).
Mice tumor vaccination
C57BL/6 mice were inoculated intraperitoneally (i.p.) with 
1 mL of DPBS containing 1x106 ID8-ova cells irradiated 
24 hours previously with a sublethal irradiation dose (2.5 
Gy). Five days following tumor inoculation, animals were 
injected intravenously (i.v.) with OT-I CD8+ T cells (2.5 
× 105cells/animal) and OT-II CD4+ T cells (5×105 cells/
animal). Vaccination with DCs (1×106 DCs/shot/animal) 
was performed i.p. on days 7, 14 and 21 following adoptive 
T cell transfer. Animals were monitored regularly for 
tumor growth. Mice attaining 30 g body weight were 
sacrificed (~40% increase in body weight over age/sex-
matched normal mice). 
Statistical analysis
SAS software (version 9.3) and StatXact Procs 9 for SAS 
were used for statistical analysis. In particular, a two-tailed 
Student’s t-test was used to compare means of continuous 
measurements between two groups. The analysis of 
variance (ANOVA) was used to compare means among 
more than two groups; differences were considered 
statistically significant when P<0.05. For animal survival, 
statistical analysis was performed with GraphPad Prism 
software using the Log-rank (Mantel-Cox) test.
Results
Squaric acid induces immunogenic necroptosis in tumor 
cells
In order to assess the role of SqA treatment in cancer 
vaccination strategies, we first set out to investigate the 
ability of SqA treatment to induce necrotic cell death or 
apoptosis in cancer cells. To this aim, we incubated ID8 
tumor cells with increasing concentrations of SqA for 
1 hour at 37°C. We observed a clear dose-dependent 
Fig. 1. Squaric acid induces immunogenic cell death in ID8 cells. (A) ID8 cells were treated with the indicated stimuli for 1 h at 37°C. Cells 
were then washed and stained for Annexin V and PI. Annexin positive cells were classed as apoptotic while necrotic cells were only PI 
positive and healthy cells were double negative. Data are representative of 3 independent experiments. (B) ID8 cells were treated with the 
indicated doses of squaric acid for 1 h and cell death was measured by PI staining. (C) ID8 cells were treated with the indicated stimuli 
for 1 h or 2 h at 37 °C. The HMGB1 oxidation status in the cell lysate was determined by western blot using the method developed by 
Makmura et al.22 Data are representative of 3 independent experiments.
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effect on the induction of cell death by increasing SqA 
concentrations, with 100% cell death at 0.3% SqA (Fig. 
1A). To determine the type of cell death induced, we 
measured PI and annexin V staining in treated cells at 
1 hour. As expected, treatment of ID8 cells with SqA 
resulted in dose-dependent necrosis within 1 hour, with 
nearly complete necrotic cell death observed at 0.06% 
SqA. Interestingly, a higher dose of 0.3% SqA resulted in 
~100% cell necroptosis, with nearly 100% cells expressing 
surface annexin V (Fig. 1B). 
Based on the observation that SqA is able to kill tumor 
cells, we next tested whether SqA induces immunogenic 
cell death (ICD), a special type of cell death that through the 
release of damage-associated molecular patterns (DAMPs) 
can induce an effective antitumor immune response.24 
One of the markers of ICD is the release of high-mobility 
group protein B1 (HMGB1).25 However, a recent study 
showed that HMGB1 is immunogenic only in its reduced 
form, but not in its oxidized state.26 In particular, the study 
showed that oxidation of Cysteine106 is necessary and 
sufficient to inactivate such immunostimulatory activity.26 
Based on this, we decided to quantify the levels of HMGB1 
cysteine oxidation using a previously established protocol 
based on SDS-PAGE mobility.22 In this assay, cysteine 
residues present in the protein sample in their oxidized 
sulfenic acid forms are covalently tagged with a ~5 kDa 
tag, causing a shift towards higher molecular weights in 
the SDS-PAGE gel which can then be revealed through 
western blot analysis. We, therefore, used this assay to 
measure HGMB1 oxidation levels in the ID8 cells treated 
with increasing concentration of SqA. Interestingly, we 
observed that 1h treatment with 0.06% or 0.3% SqA did 
not result in detectable levels of HMGB1 oxidation (no 
band shift towards higher molecular weights; Fig. 1C). 
However, prolonged SqA treatment for 2 hours induced 
detectable levels of cysteine oxidation to sulfenic acid of 
HMGB1 at both 0.06% and 0.3% tested concentrations 
(Fig. 1C). Thus, cell treatment for 1 hour with 0.3% or 
0.06% SqA efficiently induced tumor cell death while 
preserving the reduced state of HMGB1. Due to the 
reported immunogenicity of HMGB1 in its reduced 
form26 we, therefore, restricted SqA treatments to 1 hour 
in the following experiments. 
DCs pulsed with SqA-killed tumor cells stimulate 
antigen-specific T cells
To test the immunogenicity of SqA-killed tumor lysate, 
we used ovalbumin (ova) as a model antigen. To this aim, 
we generated an ova expressing ID8 cell line (ID8-ova) by 
stably transfecting ID8 cells with the chicken ovalbumin 
gene. Importantly, preliminary western blot and ELISA 
analyses confirmed that ova was expressed to detectable 
levels and stable throughout multiple cell passages in 
this cell line, validating the use of ID8-ova in subsequent 
immunological tests following ova antigen-specific 
responses (Fig. S1A and B, Supplementary Data). Next, 
ID8-ova cells were killed with 0.06% SqA for 1hr (ID8-ova-
Sq) followed by 6 freeze-thaw cycles. As a control lysate, 
ID8-ova cells were killed with 60 µM HOCl followed by 
6 freeze-thaw cycles (ID8-ova-HOCl). The so-generated 
lysates were then used to pulse DCs differentiated from 
bone marrow cells with GM-CSF and IL-4 (4-DCs), 
followed by DC maturation with LPS and IFNγ for ~18 
hours. We compared the above DCs pulsed with tumor 
lysate to DCs differentiated from bone marrow cells with 
GM-CSF and IFNα instead of IL-4 (α-DCs), which were 
pulsed with ID8-ova-HOCl or ID8-ova-Sq tumor lysate 
and matured with LPS and IFNγ for ~18 hours. Antigen-
pulsed mature DCs (4-DCs and α-DCs) were incubated 
with ova-specific CD8+ T cells (OT-I) and CD4+ T cells 
Fig. 2. Squaric acid antigen treatment and differentiation of DCs 
in the presence of IFNα lead to favorable cytokine secretion by 
antigen-specific T cells in DC-T cells co-cultures. (A, B) DCs 
were pulsed with the indicated tumor antigens overnight and 
subsequently matured with LPS and IFNγ overnight. DCs were 
then co-cultured with OT-I or OT-II cells at a 1:10 ratio at 37°C for 
24 h; levels of IFNγ (A) and IL-4 (B) were measured by ELISA. 
Results are represented as mean ± SD of at least 3 independent 
experiments. Significant differences were assessed with unpaired 
Student’s t test and indicated with asterisks: * P < 0.05; ** P < 0.01. 
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(OT-II) in co-culture assays for 24 hours, and IFNγ and 
IL-4 secreted levels were measured in the supernatant. 
DCs pulsed with tumor lysate prepared with SqA or 
HOCl elicited significantly higher IFNγ production in both 
OT-I and OT-II co-cultures compared to DCs pulsed with 
freeze-thaw lysate, extending our previous observation for 
HOCl20 also to the newly tested SqA treatment (Fig. 2A). 
Furthermore, relative to DCs pulsed with HOCL lysate, 
DCs pulsed with SqA lysate elicited significantly higher 
IFNγ responses in OT-1 cells, and among them, α-DCs 
appeared significantly superior to 4-DCs. The two lysates 
were similar in terms of OT-II IFNγ responses, but again 
α-DCs elicited significantly higher responses than 4-DCs. 
Thus, α-DCs appeared superior to 4-DCs when pulsed 
with oxidized tumor lysate, and α-DCs pulsed with SqA 
lysate elicited stronger class I responses.
SqA lysate-pulsed DCs elicited significantly lower 
IL-4 production in OT-I cells relative to HOCL lysate-
pulsed DCs (Fig. 2B). Furthermore, α-DCs elicited 
significantly less IL-4 in all conditions relative to 4-DCs, 
and specifically, when α-DCs were pulsed with SqA lysate 
we detected no IL-4 in output OT-I cells, indicating a very 
strong type I polarization. 
Hence, results from these in vitro experiments 
not only confirmed previous evidence for improved 
immune responses elicited by HOCl-oxidized antigens 
but highlighted also squaric acid as an alternative and 
even more immunogenic treatment of antigens worthy 
of further study and characterization. Concerning the 
different stimuli tested for DC preparation, our data 
Fig. 3. Effects of different antigens and differentiation stimuli used to prepare DCs on their mature phenotype and intracellular cytokine 
profile. (A) DCs were prepared as indicated in Fig. 2. The expression levels of indicated markers were then assessed by antibody staining 
followed by FACS analysis. The net mean fluorescence intensity (ΔMFI = Raw MFI-MFI of Isotype) for each marker is reported in the 
graph. Data are representative of 3 independent experiments. Student’s t test results comparing α-DCs to 4-DCs pulsed with the same 
antigen are indicated with asterisks: ** P < 0.01. (B) DCs were incubated with brefeldin A for 4 h at 37°C. Cells were then stained for CD14, 
F4/80, MHC-I, MHC-II, CD86 and CD83; subsequently permeabilized and stained for IFNγ, IL-12p70, TNFα, TGFβ and IL-10. Cells were 
analyzed by flow cytometry and results reported as net MFI for each cytokine. Data are representative of 3 independent experiments. 
Student’s t test results comparing α-DCs to 4-DCs pulsed with the same antigen are indicated with asterisks: * P < 0.05, ** P < 0.01.
Figure 3
B
A
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importantly demonstrated the superiority of α-DCs 
compared to the “canonical” 4-DCs, at least in terms of 
favorable in vitro cytokine production. 
α-DCs pulsed with SqA lysate are more immunogenic 
Based on the above results we investigated further the 
effects of the different stimuli on DC maturation. To this 
aim, we measured levels of common markers for DC 
maturation such as CD14, F4/80, MHC-II, CD86 and 
CD83 by FACS. Interestingly, when comparing 4-DCs 
to α-DCs pulsed with the same antigen source (or kept 
unpulsed), a general trend was observed with a marked 
decrease in CD14 and F4/80 expression and increase in 
MHC-I, CD83 and CD86 in α-DCs, all indicative of a 
more mature and immunogenic DC phenotype (Fig. 3A). 
On the other hand, we also observed a lower expression of 
MHC-II molecules in α DCs compared to 4-DCs, which 
may lead to impaired CD4+-dependent immune responses 
(Fig. 3A). Instead, no significant differences were recorded 
between α-DCs pulsed with tumor lysates prepared with 
SqA or HOCl compared to α-DCs pulsed with freeze-
thaw lysate. The same was true also for 4-DCs, except 
for a significant increase in MHC-I expression levels 
in 4-DCs pulsed with SqA or HOCl lysate compared to 
freeze-thaw lysate (P ≤ 0.05, Fig. 3A). Thus, these results 
confirm the previously published observation that HOCl 
antigen treatment do not contribute to DC maturation27 
(notably no effect on CD83 and MHC-II levels) and that 
a second maturation stimuli (such as LPS and IFNγ in 
our case) is necessary to reach a full maturation status, 
extending this observation also to SqA. On the other 
hand, these results importantly demonstrate that HOCl or 
SqA antigen treatments do not minimally interfere with 
DC maturation but actually improve their immunogenic 
phenotype in the few instances indicated. 
To further assess the immunogenicity of the different 
DC preparations in the study, we then also measured the 
in vitro production of the immunostimulatory cytokines 
IFNγ, IL-12p70 and TNFα and immunoregulatory 
cytokines TGFβ and IL-10 by antibody intracellular 
staining (Fig. 3B). Importantly, results showed that α-DCs 
always produced significantly higher IL-12p70 than 
4-DCs (comparing same antigen source), and also more 
IFN-γ, less IL-10 and less TGFβ in the case of SqA lysate; 
suggesting once again a more immunogenic phenotype. 
In terms of comparisons between different antigen 
Fig. 4. Squaric acid antigen treatment and differentiation of DCs in the presence of IFNα prolongs animal survival in a vaccination mouse 
model of ovarian cancer. (A) Vaccination scheme: mice were inoculated with irradiated ID8-ova cells at day 0, followed by adoptive transfer 
of OT-I and OT-II cells at day 5. Subsequently mice were vaccinated with the indicated DCs on days 7, 14 and 21 following adoptive T 
cell transfer (n= 20 for each group). (B) Animal survival was evaluated until body weight increased up to 30g and plotted in Kaplan–Meier 
cumulative survival plots. Student’s t test results (compared to placebo) are indicated with asterisks: * P < 0.05, ** P < 0.01. 
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sources, the analyses here presented showed that both 
4-DCs and α-DCs produced significantly less IL-10 when 
pulsed with HOCl or SqA lysates, compared to their freeze-
thaw pulsed counterparts (P < 0.05, Fig. 3B). A significant 
increase in IL-12p70 production was also observed in 
α-DCs stimulated with HOCl or SqA lysates, compared 
to freeze-thaw lysate (P < 0.05), while the same was not 
true in the case of 4-DCs (no significant differences, Fig. 
3B). On the other hand, no significant differences were 
recorded instead between the HOCl and the SqA lysate 
conditions, suggesting a similar effect at least on the 
expression of the tested cytokines by 4-DCs or α-DCs. 
Taken altogether, the results here presented demonstrated 
therefore that treating antigens with HOCl or SqA 
improves the immune fitness of DC vaccine formulations 
without affecting patterns of expression of important 
immunostimulatory DC surface markers. Moreover, 
these analyses also suggested that DCs differentiated 
in the presence of IFNα (α-DCs) possess advantageous 
DC phenotypes compared to more “classical” 4-DCs, 
supporting, therefore, their potential use in in vivo cancer 
vaccine approaches. As in the previous case of DC-T cell 
co-cultures (Fig. 2A, B) the combination of ID8-ova-Sq 
as antigen source with α-DCs overall showed the best 
immune fitness profile for the tested biomarkers. 
Vaccination with α-DCs pulsed with SqA lysate prolongs 
animal survival in the ID-8 tumor model
We tested whether the considered DC types pulsed with 
the different tumor lysate preparations were able to control 
ID8-ova tumor growth and increase animal survival 
in mice. To this aim, we used ID8-ova cells to establish 
intraperitoneal orthotopic tumors in sublethally irradiated 
wild-type mice (day 0) and performed an intravenous 
adoptive transfer of OT-I CD8+ and OT-II CD4+ cells on 
day 5, prior to vaccination. Animals were then vaccinated 
3 times with the indicated DC vaccine inoculated i.p. 
every 7 days from initial tumor inoculation (Fig. 4A), and 
were followed for up to 120 days post-tumor inoculation. 
Tumor evolution was assessed by body weight, which in 
this model captures ascites fluid accumulation, and by 
overall survival.
Body weight assessment showed that vaccination with 
ID8-ova-Sq pulsed α-DCs resulted in a slower increase 
in body weight (slower accumulation of ascites) in 
approximately 40% of the vaccinated animals compared 
to the other groups, while no significant differences 
were observed among the rest of the groups (Fig. S2, 
Supplementary Data). Vaccination with either 4-DCs or 
α-DCs pulsed with ID8-ova-HOCl lysate determined a 
median survival increase of ~16-20 days and ~23-35 days 
compared to control untreated mice (Fig. 4B), indicating a 
beneficial effect of HOCl oxidation of antigens on overall 
animal survival, as previously reported.20 Interestingly, 
in the case of DCs pulsed with ID8-ova-HOCl a slight 
survival improvement of ~4 days was observed with α-DCs 
over 4-DCs, although not statistically significant. For DCs 
pulsed with ID8-ova-Sq a median survival improvement of 
~10 days over untreated controls was observed in animals 
vaccinated with 4-DCs, close to statistical significance 
(P = 0.059). On the other hand, a larger median survival 
improvement of ~31 days over untreated controls was 
observed in the case of α-DCs pulsed with ID8-ova-Sq. 
Importantly, among the different vaccine formulations 
tested, this latter condition was the one characterized by 
the longest median animal survival with an improvement 
close to significance compared to either 4-DCs pulsed 
with the same antigen source (P = 0.056) or α-DCs pulsed 
with ID8-ova-HOCl (P = 0.055). Taken together, in the 
ID8 model IFNα-differentiated DCs pulsed with SqA 
treated cell lysates produced a significant improvement in 
overall survival. 
Discussion
Ester derivatives of SqA, like squaric acid dibutylester 
(SADBE) have been clinically used to treat human 
papillomas for a long time and were also previously 
shown to possess immunomodulatory properties.28 SqA is 
a known inhibitor of glyoxalase I,29 which is upregulated 
in aggressive cancers including ovarian cancer30 and it 
is able to convert methylglyoxal, a cytotoxic byproduct 
of glycolysis, into D-Lactate.29 From a chemical point of 
view, SqA is a highly reactive molecule; thanks to both 
its ring strain and the presence of an α, β-unsaturated 
carbonyl moiety it can participate in a plethora of 
reactions, usually favored by ring opening and relaxation. 
Like HOCl, derivatives of SqA can also promote radical-
mediated redox reactions,31 but contrary to the former, 
SqA can also act in addition as a direct cross-linking 
agent between 2 amine groups of 2 distinct proteins or 
peptides.32 Interestingly, this property of SqA has been 
recently used to increase the potency of a MUC1 vaccine 
by covalently cross-linking the MUC1 epitope to three 
different T-helper-cell epitopes.33 
Our group19,20,34,35 and others27,36-38 have previously 
reported on the increased immunogenicity of cancer 
antigen(s) treated with HOCl; however HOCl is a rather 
unstable molecule characterized by a short half-life. Given 
the higher stability and longer shelf life of squaric acid, 
its current use in the clinic (hence its availability in GMP 
grade and clinically approval) and its high reactivity and 
additional cross-linking properties, we therefore decided 
to investigate in this work the immunogenic properties 
of SqA treatment of cancer antigens in the context of DC 
cancer vaccination. We also theorized that the addition of 
IFNα during the differentiation of DCs, could replicate 
some of the signals associated with the HPV infection and 
perhaps enhance the effect of SqA. 
Our results indicated that SqA is able to induce tumor 
cell death in cancer cells. Importantly, we were able to show 
that this treatment does not impact on the oxidation status 
of HMGB1, preserving this important DAMP signal in its 
immunogenic reduced form,26 at least when limited to 1 
hour. When tested in vitro, DCs pulsed with tumor cells 
Dendritic cells-based cancer vaccine
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treated with SqA (ID8-ova-Sq) were more potent inducers 
of a Th1 type response than untreated cells (ID8-ova), 
as they led to both higher IFNγ production by antigen-
specific CD8+ and CD4+ T-cells. In addition, α-DCs pulsed 
with ID8-ova-Sq lysate outperformed α-DCs pulsed with 
ID8-ova-HOCl lysate in terms of CD8 response. 
Alongside testing new cell antigen treatments to 
increase their immunogenicity, we also implemented a 
different cytokine cocktail used to differentiate DCs from 
their bone marrow precursors in an effort to obtain a more 
powerful cell preparation for cancer vaccine therapies. 
Indeed, we found that “canonical” mouse 4-DCs induced 
a sustained IL-4 production in DC-T cell co-cultures, at 
least in vitro, which can be detrimental in the context of 
cancer vaccination.39 In addition to this, previous evidence 
suggested that DCs pulsed with whole tumor cell lysates 
have lower IL-12p70 production, a feature associated with 
impaired p38 MAPK signaling.40 We, therefore, decided 
to introduce IFNα in substitution of IL-4 in the system, in 
an attempt to re-activate this pathway.41,42 An additional 
reason to introduce IFNα was to mimic signals from a viral 
infection, which in the case of papilloma may synergize with 
SqA to produce a curative immune response. In doing so 
we observed that, compared to conventional 4-DCs, DCs 
differentiated in the presence of IFN-α (α-DCs) generally 
expressed higher levels of MHC-I and CD86 and lower 
levels of F4/80, indicative of a more mature phenotype 
and a potential better interaction with CD2843,44 leading 
to subsequent CD8+ T-cell increased activation. Moreover, 
α-DCs stimulated higher production of IFNγ and lower 
IL-4 production by both CD8+ and CD4+ T-cells in an 
antigen-specific manner compared to 4-DCs pulsed with 
the same antigen source, at least in vitro. 
Importantly, the modality of lysate preparation did not 
affect these maturation markers, indicating that exposure 
of tumor cells to HOCl and even more so to SqA enhances 
DC performance presumably through enhanced cross-
presentation of tumor antigen. In agreement with these 
observations, animals vaccinated with α-DCs pulsed 
with ID8-ova-Sq exhibited significantly slower ascites 
accumulation and the best overall survival among tested 
conditions. 
So far, several methods have been implemented to 
improve the immunogenicity of whole tumor antigen(s) for 
DC vaccination, from UV irradiation20,45 to heat shock46,47 
or high hydrostatic pressure48 (see18 for a review). It is 
generally believed that these different treatments improve 
immunogenic potential by increasing exposure/release of 
DAMPs as a consequence of cell stress.18 Similarly, SqA 
treatment may induce the expression of proteins with 
adjuvant properties or neutralize proteins with the reverse 
function in tumor cells, hence having a positive impact 
on downstream immune responses. An alternative or 
complementary explanation is that squaric acid may react 
with tumor proteins introducing chemical changes (e.g. 
alteration in the redox status, cross-linking, aggregation 
etc) that could potentially favor either uptake by antigen 
What is the current knowledge?
√ Dendritic cells (DCs) process and present antigens on their 
surface to stimulate T cell responses against pathogens.
√ DC vaccines have been used in the clinic for cancer therapy, 
although with only moderate success so far.
What is new here?
√ Treating tumor cell antigens with squaric acid increases 
their immunogenicity.
√ DCs differentiated with IFNα from their precursors present 
a more immunogenic phenotype.
√ Both treatments increased animal survival in a tumor 
mouse model supporting the clinical translation of this 
promising novel DC vaccine formulation.
Research Highlights
presenting cells, proteolysis, antigen processing, cross-
presentation or a combination of the above explaining in 
this way the increased immunogenicity experimentally 
observed. In particular, this possibility has already been 
shown in a few proof-of-principle studies showing 
that administration of a conjugate vaccine obtained 
by SqA-mediated chemical cross-linking of different 
peptide epitopes33 (or a protein carrier with a bacterial 
carbohydrate)49,50 increased induced antigen-specific 
immune responses. A higher stability towards metabolic 
degradation has been proposed to explain such results.33 
In any case, chemical cross-linking may well just represent 
only a partial explanation for the overall improved 
immunogenicity and further tests in this direction (e.g. 
mass spectrometry-based approaches) will help to prove 
these hypotheses elucidating the exact mechanisms of 
action of squaric acid.
Nonetheless, the observations here presented, together 
with the increased stability and clinically approved use 
of SqA above mentioned, support further clinical testing 
of SqA treatment of tumor antigen in future DC vaccine 
trials. 
Conclusion
Improving current dendritic cancer cell therapies will 
potentially provide for new and more potent personalized 
approaches to treat cancer. Our study illustrates that 
squaric acid treatment of tumor cell antigens greatly 
improves their immunogenicity stimulating a more 
effective immune response. Further to this, we also 
showed that when coupled with DCs generated with 
GM-CSF and IFNα instead of the canonical GM-CSF and 
IL-4 differentiation cocktail, this vaccine was particularly 
powerful in prolonging animal survival in an ovarian 
cancer mouse model. These results support future efforts 
aimed at translating this approach into the clinic. Such 
efforts could in fact importantly contribute to improve 
DC-based immunotherapies which showed so far only 
moderate success and thus help to exploit their full 
Mookerjee et al
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recognized (but still covered) potential.51,52
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